36 results about "Cytidine diphosphate" patented technology

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The invention relates to a fluorescent probe, which belongs to the technical field of fine chemical engineering, and discloses a rhodamine fluorescent probe with a pseudo nucleic acid base as a recognition site and preparation thereof and application to a nucleotide image. The ring opening of rhodamine lactone is induced between amino naphthyridine and nucleic acid base through a base analogue complementary hydrogen bond effect, and the selective response of specific nucleotide is realized by using the weakness of electrostatic interaction between imine positive ions generated by a ring opening product and phosphoric acid link negative ions with proper length. The probe shows good selectivity to cytidine diphosphate (CDP) and adenosine triphosphoric acid (ATP). Hela cell copolymerization focal imaging experiments show that the probe can produce a sensitive imaging effect on the nucleotide in the cell, the cell state is good after and before imaging, and the probe has small cell toxicity. Since the probe has good bioavailability and a high-sensitivity imaging effect, the probe is widely applied to medical fluorescent imaging.

The invention discloses a method for separating purified cytidine diphosphate choline by hydrophobic chromatography. The method comprises the following steps of: (1), performing enzyme inactivation, centrifugation and ultra-filtration of a cytidine diphosphate choline conversion liquid; (2), after adjusting the pH of the pre-processed cytidine diphosphate choline conversion liquid to between 2.0 and 14.0, adding an inorganic salt to prepare column-loading liquid which contains 0.01 to 5mol/L of inorganic salt and 0.1 to 40g/L of cytidine diphosphate choline with the cytidine diphosphate choline conversion liquid, absorbing the column-loading liquid with a hydrophobic chromatography resin and eluting with pure water of which the pH value is 2.0 to 14.0; and (3), nano-filtering, desalinating and concentrating the eluate, and obtaining the cytidine diphosphate choline through crystallization. In the method, the separation process is simple; through regeneration, the resin after elution can be repeatedly used; the separation cost is low; the product is easily crystallized; and the CDP-choline product with high purity and high yield can be obtained.

The invention relates to a manufacturing method of disodium cytidine triphosphate, which comprises the following steps: proceeding enzymatic conversation with CMP material; proceeding ion exchange column chromatography; separating and purifying. The enzymatic conversation reaction principle is that: brewers' yeast gets the needed enzyme liquid of the enzymatic conversation reaction; brewers' yeast produces a plurality of biological enzyme as sugar glycolysis enzyme and phosphorylase with high sugar glycolysis ability; the biological energy produced by glycolysis glucose with sugar glycolysis enzyme is transferred to cytidine monophosphate by ATP; cytidine monophosphate and phosphate radical combines to form cytidine triphosphate with the effect of phosphorylase. The method shapes low cost, simple operation, high production, high product purity by optimization, which comprises the following steps: getting enzyme liquid; proceeding enzymatic conversation by adding the main material cytidine monophosphate, monobasic potassium phosphate of proper quantity and glucose; getting product by deposition, ion exchange column chromatography, segregation, purification, refining and vacuum drying.

The invention relates to a process for preparing cytidine diphosphate choline. According to the method, denovo synthesis of pyrimidine is utilized as a basic reaction and choline materials are subjected to a reaction at the reaction temperature ranging from 20 DEG C to 38 DEG C for 10 to 72 hours with pH controlled at 5 to 7.5 in the presence of culture solution of microorganism A or further in the presence of culture solution of microorganism B or treatment so as to accumulatively produce cytidine diphosphate choline. Simple starting materials of carbon and nitrogen sources are utilized, in culture solution containing the choline materials, precursor of the cytidine diphosphate choline, namely cytidine monophosphate is synthesized by means of metabolic process, and cytidine diphosphate choline is cumulatively produced in the reaction solution. According to the method, expensive cytidine monophosphate or the precursor materials are avoided so that the preparing cost of the cytidine diphosphate choline is greatly reduced.

The invention relates to an artemisia apiacea4-(5'-cytidine diphosphate)-2-C-methyl-D-erythritol synthase coding sequence in the technical field of gene engineering. The sequence is a sequence generated after one or a plurality of codons in nucleotide are replaced by degenerate codons of amino acid with same coding, as shown in 18-position to 926-position of SEQ ID NO: 3 or shown in 18-position to926-position of SEQ ID NO: 3. The method for improving the content of plant artemisinin by using the coding sequence includes the steps of: connecting the coding sequence to a plant expression regulatory sequence and constructing a plant expression carrier containing the coding sequence; transferring the expression carrier in step 1 to agrobacterium rhizogenes, then transferring agrobacterium rhizogenes to artemisia apiacea; through antibiotic screening, obtaining a transformation cell containing the coding sequence and regenerating a transgenosis plant. The invention relates to a polypeptide, and the sequence is shown in SEQ ID NO: 4. The coding sequence can improve the content of artemisinin in artemisia apiacea and the content of isoprene compound of other plants.

The invention discloses a preparation method of uridine-5'-monophosphate disodium. The method comprises the following steps: (1) mixing cytidine monophosphate (CMP) or sodium salt, sodium nitrite and deionized water, dropwise adding acid and/or acid anhydride, continuously reacting for 0-6 hours after completing dropwise adding to obtain reaction solution 1; (2) if residual quantity of CMP is lower than 1%, adjusting the pH value of the reaction solution 1 to 6.4-7.2 to obtain reaction solution 2; (3) mixing the reaction solution 2 and 95v/v% of ethyl alcohol, crystallizing and filtering to obtain a uridine-5'-monophosphate disodium crude product; (4) mixing the uridine-5'-monophosphate disodium crude product and water, and adjusting the pH value to 7.0-8.5 to obtain reaction solution 3; and (5) mixing the reaction solution 3 and an organic solvent, recrystalizing and filtering to obtain the uridine-5'-monophosphate disodium.

The invention discloses an amphipathic Eu (III) complex as well as a preparation method and application thereof in detection for cytidine triphosphate. The structural formula of the complex is as shown in the specification. The amphipathic Eu (III) complex is formed by matching a ligand with Eu (III), wherein a compound which takes octadecyl as hydrophobic tail part and takes 1,4,7,10-tetraazacyclododecane as a hydrophobic head part serves as the ligand. The preparation method is simple and the reaction condition is mild. The amphipathic Eu (III) complex provided by the invention has the characteristics of long fluorescent lifetime, large stokes shift and unsaturated coordination; a super-molecule sensing interface is assembled and formed in a water phase; the energy donor alpha-naphthyl phosphate sodium is introduced into the system and the amphipathic Eu (III) complex serves as an energy receptor for receiving energy and emitting Eu (III) characteristic light; when the cytidine triphosphate is contained in a to-be-detected sample, the alpha-naphthyl phosphate sodium on the surface of the self-assembly body is replaced by the cytidine triphosphate, so that the fluorescence is quenched and the selective identification for the cytidine triphosphate is realized.

The invention discloses a genetic engineering preparation method of cytidine triphosphate. In the method, a culture or a treatment substance of single genetic engineering strain is used as an enzyme source; during catalysis, ammonium chloride, saratin and the like are used for reaction, so that the cytidine triphosphate is generated in a reaction solution and accumulated and is extracted from the reaction solution. The invention has the benefits that: (1) the reaction is easier to control due to the adoption of the microbial catalytic reaction ; (2) the cost of a substrate is lower and the cytidine triphosphate can be produced at low cost; and (3) the reaction is quick and the conversion rate is higher. The genetic engineering preparation method can be widely applied to preparation of the cytidine triphosphat.

The invention belongs to a preparation method of poly i-c and belongs to the technical field of biomedicine. The preparation method includes: utilizing inosine diphosphate to prepare polyinosinic acid, and using cytidine diphosphate to prepare polycytidylic acid; utilizing the prepared polyinosinic acid to react with the polycytidylic acid to obtain a high-purity poly i-c product. Poly i-c is prepared through self-developed high-purity polyinosinic acid and polycytidylic acid, so that prepared poly i-c is high in purity, and treatment difficulty in the process of preparing is lowered.

The invention discloses a preparation method of powdery cytidine triphosphate or a sodium salt of cytidine triphosphate. The preparation method comprises the following steps: mixing and precipitating an acid solution containing cytidine triphosphate or the sodium salt of cytidine triphosphate with methanol of which the volume is 5-20 times of that of the acid solution so as to obtain powdery cytidine triphosphate or the sodium salt of powdery cytidine triphosphate, or the preparation method comprises the following steps: (1) mixing the acid solution containing cytidine triphosphate or the sodium salt of cytidine triphosphate with a first organic solvent of which the volume is 2-20 times of that of the acid solution so as to obtain a first precipitate; (2) mixing the first precipitate with ethanediol or glycerin of which the volume is 2-20 times of that of the first precipitate so as to obtain a dissolved solution; (3) mixing and precipitating the dissolved solution with a second organic solvent of which the volume is 2-20 times of that of the dissolved solution so as to obtain powdery cytidine triphosphate or the sodium salt of powdery cytidine triphosphate.

The invention discloses a PLIspE gene and a coded protein and application thereof. The gene is cloned from Paeonia lactiflora by constructing a cDNA library for the first time, so a gap in separation and cloning of a 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase gene from the traditional Chinese medicine--Paeonia lactiflora is filled in. The PLIspE gene provided by the invention has a nucleotide sequence shown in SEQ ID NO. 1, or a homologous sequence obtained through addition, substitution, insertion or deletion of one or a plurality of nucleotides of the nucleotide sequence shown in SEQ ID NO. 1, or an allele of the gene or a nucleotide sequence derived from the allele. The protein coded by the gene has an amino acid sequence shown in SEQ ID NO. 2 or a homologous sequence obtained through addition, substitution, insertion or deletion of one or a plurality of amino acids of the amino acid sequence shown in SEQ ID NO. 2. The PLIspE gene can increase the content of metabolites of 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol in Paeonia lactiflora through biotechnology and has good application prospects in aspects like quality improvement of the medicinal material Paeonia lactiflora and synthetic biology of active components of Paeonia lactiflora.

Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected fromthe group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.

The invention discloses a method for synthesizing cytidine diphosphate, and belongs to the field of nucleoside synthesis in organic chemistry. The method comprises the following reaction steps that cytidine monophosphate and dichlorophosphoryl morpholine serve as raw materials, condensation is conducted under the base catalysis effect, then a crude product cytidine diphosphate is obtained through acyl chloride hydrolysis, recrystallization is conducted through an alcohol/water mixed system, and a finished cytidine diphosphate product with the HPLC purity larger than 95% is obtained. The whole reaction only comprises two steps, reaction operation is simple, and the total yield reaches 70% or above.

The invention discloses a PLIspF gene and a coded protein and application thereof. The gene is cloned from Paeonia lactiflora by constructing a cDNA library for the first time, so a gap in separation and cloning of a 2-C-methyl-D-erythritol-4-cyclodiphaophate synthase gene from the traditional Chinese medicine--Paeonia lactiflora is filled in. The PLIspF gene provided by the invention has a nucleotide sequence shown in SEQ ID NO. 1, or a homologous sequence obtained through addition, substitution, insertion or deletion of one or a plurality of nucleotides of the nucleotide sequence shown in SEQ ID NO. 1, or an allele of the gene or a nucleotide sequence derived from the allele. The protein coded by the gene has an amino acid sequence shown in SEQ ID NO. 2 or a homologous sequence obtained through addition, substitution, insertion or deletion of one or a plurality of amino acids of the amino acid sequence shown in SEQ ID NO. 2. The PLIspF gene can increase the content of metabolites of 2-phospho-4-(cytidine 5'-phospho)-2-C-methyl-D-erythritol in Paeonia lactiflora through biotechnology and has good application prospects in aspects like quality improvement of the medicinal material Paeonia lactiflora and synthetic biology of active components of Paeonia lactiflora.